Amanda R. Clause
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amanda R. Clause has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Conrad Chris Weihl
Department of Neurology, Washington University School of Medicine, Saint Louis, USA
3 shared publications - Doris G. Leung
Kennedy Krieger Institute
2 shared publications - Lindsay N. Alfano
Nationwide Children's Hospital, Columbus, OH
2 shared publications - Peter B. Kang
Department of Neurology, University of Minnesota Medical School, Minneapolis
2 shared publications - Stephanie M. Hunn
Washington University School of Medicine, 660 South Euclid Ave Campus Box 8111, St. Louis, MO 63110, USA
2 shared publications Talia Strahler
Department of Neurology, The University of Colorado–Anschutz, Aurora
2 shared publications
Latest Publications
- Open Access
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6) , e200448
Natural History of Limb Girdle Muscular Dystrophy D1 (LGMDD1)
Background and ObjectivesLimb‐girdle muscular dystrophy type D1 (LGMDD1) is caused by dominantly inherited pathogenic variants in DNAJB6, a cochaperone of HSP70. Prior work has described the clinic...
- 1 December 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (6) , e200448
Open AccessNatural History of Limb Girdle Muscular Dystrophy D1 (LGMDD1)
Background and ObjectivesLimb‐girdle muscular dystrophy type D1 (LGMDD1) is caused by dominantly inherited pathogenic variants in DNAJB6, a cochaperone of HSP70. Prior work has described the clinic...
- Open Access
- 30 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 3036
Pathogenic variants in the cohesin loader subunit MAU2 underlie a distinct Cornelia de Lange Syndrome subtype
The role of the cohesin complex depends on the cohesin loader proteins NIPBL and MAU2. While NIPBL variants are a major cause of Cornelia de Lange Syndrome (CdLS), the role of MAU2 in disease is unclear. We describe 18 individuals carrying 15 heterozygous MAU2 variants and demonstrate pathogenicity through functional analyses. In-frame MAU2 variants predominantly impair NIPBL–MAU2 interaction, whereas truncating variants cause MAU2 haploinsufficiency and lead to NIPBL reduction. Most individuals exhibit a DNA methylation profile compatible with the CdLS episignature. We also describe two MAU2 -specific episignatures that reflect variant-dependent molecular consequences. Affected individuals display a wide range of phenotypes, from classic CdLS to milder presentations, with short stature and microcephaly as major features. A heterozygous Mau2 knockout mouse model recapitulates these traits, confirming the causal role of MAU2 disruption in vivo. Our study establishes MAU2 as a CdLS-associated gene and delineates a MAU2 -related chromatinopathy with variable expressivity.
- 30 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 3036
Open AccessPathogenic variants in the cohesin loader subunit MAU2 underlie a distinct Cornelia de Lange Syndrome subtype
The role of the cohesin complex depends on the cohesin loader proteins NIPBL and MAU2. While NIPBL variants are a major cause of Cornelia de Lange Syndrome (CdLS), the role of MAU2 in disease is unclear. We describe 18 individuals carrying 15 heterozygous MAU2 variants and demonstrate pathogenicity through functional analyses. In-frame MAU2 variants predominantly impair NIPBL–MAU2 interaction, whereas truncating variants cause MAU2 haploinsufficiency and lead to NIPBL reduction. Most individuals exhibit a DNA methylation profile compatible with the CdLS episignature. We also describe two MAU2 -specific episignatures that reflect variant-dependent molecular consequences. Affected individuals display a wide range of phenotypes, from classic CdLS to milder presentations, with short stature and microcephaly as major features. A heterozygous Mau2 knockout mouse model recapitulates these traits, confirming the causal role of MAU2 disruption in vivo. Our study establishes MAU2 as a CdLS-associated gene and delineates a MAU2 -related chromatinopathy with variable expressivity.
- Open Access
- 16 April 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (6) , 1179-1186
Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study
Objective: Identifying functional measures that are both valid and reliable in the limb girdle muscular dystrophy (LGMD) population is critical for quantifying the level of functional impairment related to disease progression in order to establish clinical trial readiness in the context of anticipated therapeutic trials.Methods: Through the Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP‐LGMD) Consortium, 42 subjects with LGMDR1 were enrolled in a 12‐month natural history study across 11 international sites. Each subject completed a battery of clinical outcome assessments (COA), including the North Star Assessment for Limb Girdle‐Type Dystrophies (NSAD), 10‐m walk/run, and Performance of the Upper Limb (PUL), in addition to several patient‐reported outcome measures (PROM).Results: In this baseline cross‐sectional analysis, significant correlations were found between COAs and PROMs, with significant differences in the performance of assessments based on subjects' ambulatory status and genetic variant classification.Interpretation: The study has determined that the NSAD and other assessments are valid and reliable measures for quantifying the level of disease impairment in individuals with LGMDR1.
- 16 April 2025
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 12 (6) , 1179-1186
Open AccessClinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study
Objective: Identifying functional measures that are both valid and reliable in the limb girdle muscular dystrophy (LGMD) population is critical for quantifying the level of functional impairment related to disease progression in order to establish clinical trial readiness in the context of anticipated therapeutic trials.Methods: Through the Genetic Resolution and Assessments Solving Phenotypes in LGMD (GRASP‐LGMD) Consortium, 42 subjects with LGMDR1 were enrolled in a 12‐month natural history study across 11 international sites. Each subject completed a battery of clinical outcome assessments (COA), including the North Star Assessment for Limb Girdle‐Type Dystrophies (NSAD), 10‐m walk/run, and Performance of the Upper Limb (PUL), in addition to several patient‐reported outcome measures (PROM).Results: In this baseline cross‐sectional analysis, significant correlations were found between COAs and PROMs, with significant differences in the performance of assessments based on subjects' ambulatory status and genetic variant classification.Interpretation: The study has determined that the NSAD and other assessments are valid and reliable measures for quantifying the level of disease impairment in individuals with LGMDR1.
- Open Access
- 30 August 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (9) , 2268-2276
Expert panel curation of 31 genes in relation to limb girdle muscular dystrophy
Objective: Limb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD.Methods: The ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene–disease relationships (GDR) using the ClinGen gene–disease clinical validity framework to evaluate 31 genes implicated in LGMD.Results: The GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes (CAPN3, COL6A1, COL6A2, and COL6A3) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as definitive, 4 (11%) as moderate, and 1 (3%) as limited. Two genes, POMGNT1 and DAG1, though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD.Interpretation: The expert‐reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case‐level data that help clarify disputed or novel LGMD associations.
- 30 August 2024
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 11 (9) , 2268-2276
Open AccessExpert panel curation of 31 genes in relation to limb girdle muscular dystrophy
Objective: Limb girdle muscular dystrophies (LGMDs) are a group of genetically heterogeneous autosomal conditions with some degree of phenotypic homogeneity. LGMD is defined as having onset >2 years of age with progressive proximal weakness, elevated serum creatine kinase levels and dystrophic features on muscle biopsy. Advances in massively parallel sequencing have led to a surge in genes linked to LGMD.Methods: The ClinGen Muscular Dystrophies and Myopathies gene curation expert panel (MDM GCEP, formerly Limb Girdle Muscular Dystrophy GCEP) convened to evaluate the strength of evidence supporting gene–disease relationships (GDR) using the ClinGen gene–disease clinical validity framework to evaluate 31 genes implicated in LGMD.Results: The GDR was exclusively LGMD for 17 genes, whereas an additional 14 genes were related to a broader phenotype encompassing congenital weakness. Four genes (CAPN3, COL6A1, COL6A2, and COL6A3) were split into two separate disease entities, based on each displaying both dominant and recessive inheritance patterns, resulting in curation of 35 GDRs. Of these, 30 (86%) were classified as definitive, 4 (11%) as moderate, and 1 (3%) as limited. Two genes, POMGNT1 and DAG1, though definitively related to myopathy, currently have insufficient evidence to support a relationship specifically with LGMD.Interpretation: The expert‐reviewed assertions on the clinical validity of genes implicated in LGMDs form an invaluable resource for clinicians and molecular geneticists. We encourage the global neuromuscular community to publish case‐level data that help clarify disputed or novel LGMD associations.